Yanting Luo
University of Notre Dame
6 Papers
20 Citations
Yanting Luo is an academic researcher from University of Notre Dame. The author has contributed to research in topics: Carcinogenesis & Cancer. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
UQCRH downregulation promotes Warburg effect in renal cell carcinoma cells.
Yanting Luo,Louise Medina Bengtsson,Xuechun Wang,Tianhe Huang,Guoqiang Liu,Sean V. Murphy,Caiqin Wang,John Koren,Zachary T. Schafer,Xin Lu +9 more
TL;DR: This study suggests that loss of UQCRH expression by hypermethylation may promote kidney carcinogenesis through exacerbating the functional decline of mitochondria thus reinforcing the Warburg effect.
An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.
Xin Lu,Xin Lu,Xin Lu,Xiaolu Pan,Chang-Jiun Wu,Di Zhao,Shan Feng,Yong Zang,Rumi Lee,Sunada Khadka,Samirkumar B. Amin,Eun-Jung Jin,Xiaoying Shang,Pingna Deng,Yanting Luo,William R. Morgenlander,Jacqueline Weinrich,Xuemin Lu,Shan Jiang,Qing Chang,Nora M. Navone,Patricia Troncoso,Ronald A. DePinho,Y. Alan Wang +23 more
TL;DR: Results indicate that PYGO2 functions as a driver oncogene in the 1q21.3 amplicon and may serve as a potential prognostic biomarker and therapeutic target for metastatic prostate cancer.
Experimental study on synergistic effect of HIFU treatment of tumors using Bifidobacterium bound with cationic phase-change nanoparticles.
B-L Jiang,X Gao,J Xiong,P-Y Zhu,Yanting Luo,D Xu,Y Tang,Y-T Wang,C-Y Chen,H-Y Yang,H Qiao,J-Z Zou +11 more
TL;DR: This study presents a biocompatible bacteria-based system that can deliver cationic phase-change nanoparticles into solid tumor to achieve enhanced imaging and treatment integration and shows a valid method in diagnosis and therapy integration.
7
An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer
Xin Lu,Xin Lu,Xin Lu,Xiaolu Pan,Chang-Jiun Wu,Di Zhao,Shan Feng,Yong Zang,Rumi Lee,Sunada Khadka,Samirkumar B. Amin,Eun-Jung Jin,Xiaoying Shang,Pingna Deng,Yanting Luo,William R. Morgenlander,Jacqueline Weinrich,Xuemin Lu,Shan Jiang,Qing Chang,Nora M. Navone,Patricia Troncoso,Ronald A. DePinho,Y. Alan Wang +23 more
- 15 Jul 2018
TL;DR: In this article, the Pygopus family PHD finger 2 (PYGO2) was identified as a driver oncogene in the 1q21.3 amplicon and may serve as a potential biomarker and therapeutic target for metastatic prostate cancer.
6
Effective combinatorial immunotherapy for penile squamous cell carcinoma
Tianhe Huang,Tianhe Huang,Tianhe Huang,Xi Cheng,Xi Cheng,Xi Cheng,Jad Chahoud,Ahmed Sarhan,Pheroze Tamboli,Priya Rao,Ming Guo,Ganiraju C. Manyam,Li Zhang,Yu Xiang,Leng Han,Xiaoying Shang,Pingna Deng,Yanting Luo,Xuemin Lu,Shan Feng,Magaly Martinez Ferrer,Y. Alan Wang,Ronald A. DePinho,Curtis A. Pettaway,Xin Lu,Xin Lu +25 more
- 01 May 2020
TL;DR: A genetically engineered mouse model of PSCC is developed by co-deletion of Smad4 and Apc in the androgen-responsive penile epithelium, and synergistic efficacy of checkpoint therapy with cabozantinib or celecoxib is shown in their model.